$SLXP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in SALIX PHARMACEUTICALS LTD.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in SALIX PHARMACEUTICALS LTD. Get notifications about new insider transactions in SALIX PHARMACEUTICALS LTD for free.
Page: < prev 1 2 3 4 5 6 ... 8 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 08 2013 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Sell | S | 49.34 | 5,000 | 246,700 | 50,566 | 55.6 K to 50.6 K (-9.00 %) |
Mar 22 2013 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Sell | S | 50.05 | 3,000 | 150,150 | 28,955 | 32 K to 29 K (-9.39 %) |
Jan 15 2013 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Sell | S | 46.19 | 3,000 | 138,570 | 31,955 | 35 K to 32 K (-8.58 %) |
Jan 07 2013 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Option Exercise | M | 7.60 | 15,000 | 114,000 | 0 | |
Jan 07 2013 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Buy | M | 7.60 | 15,000 | 114,000 | 450,224 | 435.2 K to 450.2 K (+3.45 %) |
Jan 04 2013 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Payment of Exercise | F | 40.47 | 3,149 | 127,440 | 55,566 | 58.7 K to 55.6 K (-5.36 %) |
Jan 04 2013 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Payment of Exercise | F | 40.47 | 22,268 | 901,186 | 613,613 | 635.9 K to 613.6 K (-3.50 %) |
Jan 04 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Payment of Exercise | F | 40.47 | 5,052 | 204,454 | 67,191 | 72.2 K to 67.2 K (-6.99 %) |
Jan 04 2013 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Payment of Exercise | F | 40.47 | 6,130 | 248,081 | 170,471 | 176.6 K to 170.5 K (-3.47 %) |
Dec 28 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 8.00 | 90,000 | 720,000 | 0 | |
Dec 28 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 41.44 | 60,000 | 2,486,382 | 176,601 | 236.6 K to 176.6 K (-25.36 %) |
Dec 28 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 8.00 | 90,000 | 720,000 | 236,601 | 146.6 K to 236.6 K (+61.39 %) |
Dec 21 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 7.60 | 33,750 | 256,500 | 0 | |
Dec 21 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Sell | S | 42.27 | 25,000 | 1,056,673 | 635,881 | 660.9 K to 635.9 K (-3.78 %) |
Dec 21 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 7.60 | 33,750 | 256,500 | 660,881 | 627.1 K to 660.9 K (+5.38 %) |
Dec 06 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 42.53 | 3,000 | 127,590 | 435,224 | 438.2 K to 435.2 K (-0.68 %) |
Nov 26 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 41.62 | 3,000 | 124,860 | 438,224 | 441.2 K to 438.2 K (-0.68 %) |
Nov 16 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 41.15 | 3,000 | 123,450 | 441,224 | 444.2 K to 441.2 K (-0.68 %) |
Nov 16 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 12,000 | 0 | 444,224 | 456.2 K to 444.2 K (-2.63 %) |
Nov 13 2012 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Sell | S | 40.75 | 1,725 | 70,294 | 34,955 | 36.7 K to 35 K (-4.70 %) |
Nov 13 2012 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Sell | S | 40.30 | 1,725 | 69,518 | 36,680 | 38.4 K to 36.7 K (-4.49 %) |
Jul 05 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Payment of Exercise | F | 54.44 | 6,248 | 340,141 | 146,601 | 152.8 K to 146.6 K (-4.09 %) |
Jul 05 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Payment of Exercise | F | 54.44 | 4,107 | 223,585 | 72,243 | 76.4 K to 72.2 K (-5.38 %) |
Jul 05 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Payment of Exercise | F | 54.44 | 17,357 | 944,915 | 627,131 | 644.5 K to 627.1 K (-2.69 %) |
Jul 02 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 4.07 | 228,467 | 929,861 | 0 | |
Jul 02 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Sell | S | 52.07 | 119,300 | 6,211,832 | 644,488 | 763.8 K to 644.5 K (-15.62 %) |
Jul 02 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 4.07 | 228,467 | 929,861 | 763,788 | 535.3 K to 763.8 K (+42.68 %) |
Jul 05 2012 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Payment of Exercise | F | 54.44 | 3,123 | 170,016 | 58,715 | 61.8 K to 58.7 K (-5.05 %) |
Jun 18 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 4.07 | 36,534 | 148,693 | 228,466 | |
Jun 18 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 4.07 | 36,534 | 148,693 | 535,321 | 498.8 K to 535.3 K (+7.32 %) |
Jun 07 2012 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Sell | S | 51.67 | 10,000 | 516,692 | 33,202 | 43.2 K to 33.2 K (-23.15 %) |
Jun 12 2012 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Sell | S | 51.63 | 2,550 | 131,657 | 0 | 2.6 K to 0 (-100.00 %) |
Jun 12 2012 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Sell | S | 51.63 | 7,000 | 361,410 | 75,640 | 82.6 K to 75.6 K (-8.47 %) |
Jun 07 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 4,640 | 0 | 401,864 | 406.5 K to 401.9 K (-1.14 %) |
Jun 05 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 51.49 | 3,000 | 154,470 | 406,504 | 409.5 K to 406.5 K (-0.73 %) |
May 21 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.53 | 10,000 | 175,300 | 44,200 | |
May 21 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 52.26 | 2,900 | 151,554 | 76,350 | 79.3 K to 76.4 K (-3.66 %) |
May 21 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 51.35 | 7,100 | 364,585 | 79,250 | 86.4 K to 79.3 K (-8.22 %) |
May 21 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.53 | 10,000 | 175,300 | 86,350 | 76.4 K to 86.4 K (+13.10 %) |
May 03 2012 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Sell | S | 48.91 | 1,000 | 48,910 | 33,668 | 34.7 K to 33.7 K (-2.88 %) |
Apr 27 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Grant | A | 0.00 | 20,713 | 0 | 76,350 | 55.6 K to 76.4 K (+37.23 %) |
Apr 27 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Grant | A | 0.00 | 21,711 | 0 | 152,849 | 131.1 K to 152.8 K (+16.56 %) |
Apr 27 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Grant | A | 0.00 | 85,054 | 0 | 498,787 | 413.7 K to 498.8 K (+20.56 %) |
Apr 27 2012 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Grant | A | 0.00 | 19,406 | 0 | 61,838 | 42.4 K to 61.8 K (+45.73 %) |
Apr 13 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 4.07 | 20,000 | 81,400 | 265,000 | |
Apr 13 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 4.07 | 20,000 | 81,400 | 413,733 | 393.7 K to 413.7 K (+5.08 %) |
Apr 09 2012 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Grant | A | 0.00 | 4,160 | 0 | 38,405 | 34.2 K to 38.4 K (+12.15 %) |
Apr 09 2012 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Grant | A | 0.00 | 4,160 | 0 | 43,202 | 39 K to 43.2 K (+10.66 %) |
Apr 09 2012 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Grant | A | 0.00 | 4,160 | 0 | 68,468 | 64.3 K to 68.5 K (+6.47 %) |
Apr 09 2012 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Grant | A | 0.00 | 4,160 | 0 | 82,640 | 78.5 K to 82.6 K (+5.30 %) |
Apr 09 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Grant | A | 0.00 | 4,160 | 0 | 409,504 | 405.3 K to 409.5 K (+1.03 %) |
Mar 20 2012 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Sell | S | 51.98 | 9,375 | 487,313 | 64,308 | 73.7 K to 64.3 K (-12.72 %) |
Mar 09 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 49.06 | 3,000 | 147,180 | 455,344 | 458.3 K to 455.3 K (-0.65 %) |
Mar 09 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 16,000 | 0 | 458,344 | 474.3 K to 458.3 K (-3.37 %) |
Mar 09 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 34,000 | 0 | 474,344 | 508.3 K to 474.3 K (-6.69 %) |
Mar 02 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 10,500 | 0 | 508,344 | 518.8 K to 508.3 K (-2.02 %) |
Mar 02 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 10,500 | 0 | 518,844 | 529.3 K to 518.8 K (-1.98 %) |
Mar 01 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 4.07 | 12,600 | 51,239 | 0 | |
Mar 01 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 50.09 | 12,600 | 631,134 | 131,138 | 143.7 K to 131.1 K (-8.77 %) |
Mar 01 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 4.07 | 12,600 | 51,239 | 143,738 | 131.1 K to 143.7 K (+9.61 %) |
Feb 24 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 10,500 | 0 | 19,000 | 29.5 K to 19 K (-35.59 %) |
Feb 24 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 10,500 | 0 | 29,500 | 19 K to 29.5 K (+55.26 %) |
Feb 24 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 10,500 | 0 | 529,344 | 539.8 K to 529.3 K (-1.95 %) |
Feb 15 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.53 | 4,297 | 75,326 | 54,200 | |
Feb 15 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 50.00 | 4,297 | 214,850 | 55,637 | 59.9 K to 55.6 K (-7.17 %) |
Feb 15 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.53 | 4,297 | 75,326 | 59,934 | 55.6 K to 59.9 K (+7.72 %) |
Feb 15 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 4.07 | 12,891 | 52,423 | 12,600 | |
Feb 15 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 50.00 | 12,891 | 644,550 | 131,138 | 144 K to 131.1 K (-8.95 %) |
Feb 15 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 4.07 | 12,891 | 52,423 | 144,029 | 131.1 K to 144 K (+9.83 %) |
Feb 07 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Option Exercise | M | 4.07 | 15,000 | 60,999 | 0 | |
Feb 07 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Buy | M | 4.07 | 15,000 | 60,999 | 539,844 | 524.8 K to 539.8 K (+2.86 %) |
Feb 07 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.53 | 259 | 4,540 | 58,497 | |
Feb 07 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 50.00 | 259 | 12,950 | 55,637 | 55.9 K to 55.6 K (-0.46 %) |
Feb 07 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.53 | 259 | 4,540 | 55,896 | 55.6 K to 55.9 K (+0.47 %) |
Feb 07 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 4.07 | 776 | 3,156 | 25,491 | |
Feb 07 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 50.00 | 776 | 38,800 | 131,138 | 131.9 K to 131.1 K (-0.59 %) |
Feb 07 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 4.07 | 776 | 3,156 | 131,914 | 131.1 K to 131.9 K (+0.59 %) |
Jan 26 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 3,500 | 0 | 19,000 | 22.5 K to 19 K (-15.56 %) |
Jan 26 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 6,500 | 0 | 22,500 | 16 K to 22.5 K (+40.63 %) |
Jan 26 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 6,500 | 0 | 524,844 | 531.3 K to 524.8 K (-1.22 %) |
Jan 26 2012 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 3,500 | 0 | 531,344 | 534.8 K to 531.3 K (-0.65 %) |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 4.07 | 375 | 1,525 | 26,267 | |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 4.07 | 3,358 | 13,656 | 26,642 | |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 4.07 | 375 | 1,525 | 131,138 | 131.5 K to 131.1 K (-0.29 %) |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 4.07 | 375 | 1,525 | 131,513 | 131.1 K to 131.5 K (+0.29 %) |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 50.06 | 3,358 | 168,098 | 131,138 | 134.5 K to 131.1 K (-2.50 %) |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 4.07 | 3,358 | 13,656 | 134,496 | 131.1 K to 134.5 K (+2.56 %) |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.53 | 125 | 2,191 | 58,756 | |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.53 | 1,119 | 19,616 | 58,881 | |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 50.00 | 125 | 6,250 | 55,637 | 55.8 K to 55.6 K (-0.22 %) |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.53 | 125 | 2,191 | 55,762 | 55.6 K to 55.8 K (+0.22 %) |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 50.06 | 1,119 | 56,016 | 55,637 | 56.8 K to 55.6 K (-1.97 %) |
Jan 19 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.53 | 1,119 | 19,616 | 56,756 | 55.6 K to 56.8 K (+2.01 %) |
Jan 05 2012 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Payment of Exercise | F | 47.85 | 1,160 | 55,506 | 78,480 | 79.6 K to 78.5 K (-1.46 %) |
Jan 05 2012 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Payment of Exercise | F | 47.85 | 1,040 | 49,764 | 42,432 | 43.5 K to 42.4 K (-2.39 %) |
Jan 05 2012 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Payment of Exercise | F | 47.85 | 1,439 | 68,856 | 34,245 | 35.7 K to 34.2 K (-4.03 %) |
Jan 05 2012 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Payment of Exercise | F | 47.85 | 923 | 44,166 | 34,668 | 35.6 K to 34.7 K (-2.59 %) |
Jan 05 2012 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Payment of Exercise | F | 47.85 | 9,734 | 465,772 | 393,733 | 403.5 K to 393.7 K (-2.41 %) |
Jan 05 2012 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Payment of Exercise | F | 47.85 | 1,717 | 82,158 | 39,042 | 40.8 K to 39 K (-4.21 %) |
Jan 05 2012 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Payment of Exercise | F | 47.85 | 2,506 | 119,912 | 55,637 | 58.1 K to 55.6 K (-4.31 %) |
Jan 05 2012 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Payment of Exercise | F | 47.85 | 2,852 | 136,468 | 131,138 | 134 K to 131.1 K (-2.13 %) |
Jan 05 2012 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Payment of Exercise | F | 47.85 | 1,439 | 68,856 | 73,683 | 75.1 K to 73.7 K (-1.92 %) |
Dec 12 2011 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Gift | G | 0.00 | 1,200 | 0 | 40,759 | 42 K to 40.8 K (-2.86 %) |
Dec 08 2011 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Option Exercise | M | 4.07 | 15,000 | 61,050 | 0 | |
Dec 08 2011 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Sell | S | 44.43 | 4,700 | 208,821 | 79,640 | 84.3 K to 79.6 K (-5.57 %) |
Dec 08 2011 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Buy | M | 4.07 | 15,000 | 61,050 | 84,340 | 69.3 K to 84.3 K (+21.63 %) |
Dec 05 2011 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 1,400 | 0 | 534,844 | 536.2 K to 534.8 K (-0.26 %) |
Sep 16 2011 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 450 | 0 | 4,220 | 3.8 K to 4.2 K (+11.94 %) |
Sep 16 2011 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 450 | 0 | 4,220 | 3.8 K to 4.2 K (+11.94 %) |
Sep 16 2011 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 450 | 0 | 403,467 | 403.9 K to 403.5 K (-0.11 %) |
Sep 16 2011 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 450 | 0 | 403,917 | 404.4 K to 403.9 K (-0.11 %) |
Sep 08 2011 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 29.55 | 1,360 | 40,188 | 536,244 | 537.6 K to 536.2 K (-0.25 %) |
Sep 02 2011 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 31.14 | 2,000 | 62,279 | 537,604 | 539.6 K to 537.6 K (-0.37 %) |
Aug 31 2011 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 29.69 | 1,000 | 29,690 | 539,604 | 540.6 K to 539.6 K (-0.18 %) |
Aug 11 2011 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Buy | P | 29.77 | 580 | 17,267 | 1,080 | 500 to 1.1 K (+116.00 %) |
Aug 11 2011 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Buy | P | 29.45 | 110 | 3,240 | 69,340 | 69.2 K to 69.3 K (+0.16 %) |
Jul 11 2011 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 39.60 | 13,000 | 514,764 | 58,143 | 71.1 K to 58.1 K (-18.27 %) |
Jul 06 2011 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Payment of Exercise | F | 39.83 | 9,212 | 366,914 | 71,143 | 80.4 K to 71.1 K (-11.46 %) |
Jul 06 2011 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Payment of Exercise | F | 39.83 | 5,993 | 238,701 | 43,474 | 49.5 K to 43.5 K (-12.12 %) |
Jul 06 2011 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Payment of Exercise | F | 39.83 | 1,352 | 53,850 | 75,122 | 76.5 K to 75.1 K (-1.77 %) |
Jul 06 2011 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Payment of Exercise | F | 39.83 | 1,352 | 53,850 | 35,684 | 37 K to 35.7 K (-3.65 %) |
Jul 06 2011 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Payment of Exercise | F | 39.83 | 1,090 | 43,415 | 69,230 | 70.3 K to 69.2 K (-1.55 %) |
Jul 06 2011 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Payment of Exercise | F | 39.83 | 1,614 | 64,286 | 41,959 | 43.6 K to 42 K (-3.70 %) |
Jul 06 2011 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Payment of Exercise | F | 39.83 | 11,242 | 447,769 | 133,990 | 145.2 K to 134 K (-7.74 %) |
Jul 06 2011 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Payment of Exercise | F | 39.83 | 38,447 | 1,531,344 | 404,367 | 442.8 K to 404.4 K (-8.68 %) |
Jul 06 2011 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Sell | S | 40.32 | 7,357 | 296,670 | 35,591 | 42.9 K to 35.6 K (-17.13 %) |
Jul 06 2011 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Payment of Exercise | F | 39.83 | 4,180 | 166,489 | 42,948 | 47.1 K to 42.9 K (-8.87 %) |
Jun 01 2011 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Sell | S | 38.93 | 1,675 | 65,208 | 37,036 | 38.7 K to 37 K (-4.33 %) |
May 18 2011 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.53 | 20,000 | 350,600 | 60,000 | |
May 18 2011 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 40.35 | 20,000 | 806,986 | 80,355 | 100.4 K to 80.4 K (-19.93 %) |
May 18 2011 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.53 | 20,000 | 350,600 | 100,355 | 80.4 K to 100.4 K (+24.89 %) |
May 04 2011 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Payment of Exercise | F | 39.29 | 1,623 | 63,768 | 50,505 | 52.1 K to 50.5 K (-3.11 %) |
May 04 2011 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Grant | A | 0.00 | 8,450 | 0 | 52,128 | 43.7 K to 52.1 K (+19.35 %) |
May 17 2011 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Sell | S | 39.84 | 3,377 | 134,535 | 47,128 | 50.5 K to 47.1 K (-6.69 %) |
May 04 2011 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Grant | A | 0.00 | 4,640 | 0 | 38,711 | 34.1 K to 38.7 K (+13.62 %) |
May 04 2011 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Grant | A | 0.00 | 4,640 | 0 | 43,573 | 38.9 K to 43.6 K (+11.92 %) |
May 04 2011 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Grant | A | 0.00 | 4,640 | 0 | 76,474 | 71.8 K to 76.5 K (+6.46 %) |
May 04 2011 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Grant | A | 0.00 | 4,640 | 0 | 70,320 | 65.7 K to 70.3 K (+7.06 %) |
May 04 2011 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Grant | A | 0.00 | 4,640 | 0 | 540,604 | 536 K to 540.6 K (+0.87 %) |
May 04 2011 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Grant | A | 0.00 | 22,698 | 0 | 80,355 | 57.7 K to 80.4 K (+39.37 %) |
May 04 2011 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Grant | A | 0.00 | 25,955 | 0 | 145,232 | 119.3 K to 145.2 K (+21.76 %) |
May 04 2011 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Grant | A | 0.00 | 90,807 | 0 | 442,814 | 352 K to 442.8 K (+25.80 %) |
Mar 11 2011 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Sell | S | 32.40 | 1,675 | 54,270 | 34,071 | 35.7 K to 34.1 K (-4.69 %) |
Jan 13 2011 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 6,000 | 0 | 16,000 | 10 K to 16 K (+60.00 %) |
Jan 13 2011 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 5,200 | 0 | 535,964 | 541.2 K to 536 K (-0.96 %) |
Jan 13 2011 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 6,000 | 0 | 541,164 | 547.2 K to 541.2 K (-1.10 %) |
Mar 08 2011 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Option Exercise | M | 18.87 | 22,500 | 424,649 | 0 | |
Mar 08 2011 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Option Exercise | M | 17.63 | 15,000 | 264,450 | 0 | |
Mar 08 2011 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Buy | M | 18.87 | 22,500 | 424,649 | 71,834 | 49.3 K to 71.8 K (+45.61 %) |
Mar 08 2011 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Buy | M | 17.63 | 15,000 | 264,450 | 49,334 | 34.3 K to 49.3 K (+43.69 %) |